Diagnostics

Cipla announces the launch of Daptomycin for Injection, 500 mg/vial, single-dose vials

(for intravenous use only)

Mumbai, India, & New Jersey, USA; 25th September, 2019: Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.

According to IQVIA (IMS Health), Cubicin® for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019. The product is available for shipping immediately.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Related Articles

Leave a Reply

Back to top button
Close
Close